The trial design is a US multicenter, randomized, double-blind, placebo-controlled study of subcutaneous Tovaxin in subjects with clinically isolated syndrome or relapsing/remitting multiple sclerosis. More than 60% of
Results for the trial, which evaluated TPI-1020, showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects, which could be beneficial in Topigen’s target indication
The marketing authorization applications seek approval for oral alitretinoin in the treatment of severe refractory chronic hand eczema and are based on a clinical program comprising almost 2,000
Equetro (carbamazepine) is a treatment for the acute manic and mixed episodes associated with bipolar-1 disorder – a condition where patients experience extended periods of exaggerated highs in
NGX267, a functionally selective muscarinic (M1) agonist, was found to be safe and well tolerated when given orally to healthy male volunteers once-daily for four consecutive days. In
XP19986 is formulated in a sustained-release tablet, designated as SR3. The trial demonstrated sustained levels of XP19986 over 24 hours and enabled identification of suitable doses for further
In December 2006, Innovive acquired North American rights to tamibarotene from TMRC. Tamibarotene, a novel synthetic retinoid drug candidate, will be evaluated in a Phase II pivotal trial
Based on the assessment, progression-free survival (PFS) will be the primary endpoint of the Phase III trial and overall survival will be a secondary endpoint. The company expects
MB07133 is a novel HepDirect prodrug of cytarabine monophosphate (araCMP) designed to produce the oncolytically active form cytarabine triphosphate (araCTP) in the liver tumor, where it acts to
The Phase II single-agent study is being conducted at multiple centers across the US to evaluate the safety and efficacy of MKC-1 in metastatic breast cancer patients who
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.